Skip to main content
OpenTrials
Completed

NCT Number: NCT04203784

Meropenem and Piperacillin Plasma Concentrations During CRRT

This observational study reports meropenem and piperacillin plasma concentrations in patients treated with either antibiotic and simultaneous continuous renal replacement therapy (CRRT).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sepsis Antibiotic Hemolysis Infection Infections Inflammation Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Replacement Therapy Systemic Inflammatory Response Syndrome

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Karolinska University Hospital Solna

Stockholm, 17176, Sweden

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients treated in the study ICU and
  • simultaneous CRRT and antibiotic treatment with either meropenem or piperacillin-tazobactam.

Exclusion criteria

  • none

Treatment and study plan

Plasma concentration measurements

Other

Plasma concentration measurements

Primary outcomes

  1. Plasma antibiotic concentrations at mid and end of dosing interval

    Time frame: 1 week

    We vill report the measured plasma antibiotic concentrations at the mid and end of the dosing interval.

  2. Plasma antibiotic concentrations at mid and end of dosing interval

    Time frame: 1 week

    The percentage of patients having a concentration above the highest MIC (minimal inhibitory concentration) breakpoint for pathogens considered susceptible for the antibiotic.

  3. Relationships between plasma antibiotic concentrations and CRRT dose.

    Time frame: 1 week

    We will report the correlation between measured plasma concentrations of either antibiotic and the intensity of the CRRT treatment.

  4. Influence of residual diuresis on the measured plasma antibiotic concentrations.

    Time frame: 1 week

    We will report the correlation between measured plasma concentrations of either antibiotic and residual diuresis.

Sponsors and collaborators

Lead sponsor

Karolinska University Hospital

Other

Registry information

Acronym: ABC2

Important dates

Study start
2012
Primary completion
2016
Study completion
2016
First posted
Dec 18, 2019
Registry last updated
Dec 19, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.